This compound, also known as Tinuvin 326, is a widely used UV absorber in various applications. It is a white, crystalline powder with a molecular weight of 368.5 g/mol. Its synthesis typically involves a reaction between 2-aminobenzotriazole and 2-hydroxy-3,5-di-tert-butylbenzaldehyde. Tinuvin 326 is effective in absorbing UV radiation in the range of 280-380 nm, protecting materials from photodegradation and discoloration. This compound is commonly employed in plastics, polymers, paints, coatings, and textiles to prevent UV-induced damage. The presence of two bulky tert-butyl groups in its structure contributes to its excellent UV absorption properties and thermal stability. Tinuvin 326 is known for its high efficiency, long-term effectiveness, and compatibility with various materials. Its importance lies in safeguarding materials from the detrimental effects of UV radiation, extending their lifespan and maintaining their aesthetic appeal. Extensive research focuses on understanding its mechanism of action, optimizing its performance in different applications, and exploring potential environmental impacts.'
2-(2'-hydroxy-3',5'-di-tert-butylphenyl)benzotriazole: ultraviolet absorber agent [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 77455 |
| SCHEMBL ID | 29708 |
| MeSH ID | M0517183 |
| Synonym |
|---|
| HMS1476A08 |
| OPREA1_853721 |
| us7kl87a2p , |
| 2-(2'-hydroxy-3',5'-di-tert-butylphenyl) benzotriazole |
| 2-(2'-hydroxy-3',5'-di-tert-butylphenyl)benzotriazole |
| 2-benzotriazol-2-yl-4,6-di-tert-butylphenol |
| hdbb |
| phenol, 2-(2h-benzotriazol-2-yl)-4,6-bis(1,1-dimethylethyl)- |
| einecs 223-346-6 |
| unii-us7kl87a2p |
| IDI1_020030 |
| OPREA1_185869 |
| CHEMDIV3_001064 |
| AKOS000508076 |
| 3846-71-7 |
| 2-(benzotriazol-2-yl)-4,6-ditert-butylphenol |
| 2-(2h-benzo[d][1,2,3]triazol-2-yl)-4,6-di-tert-butylphenol |
| A825098 |
| 2-(2-benzotriazolyl)-4,6-ditert-butylphenol |
| 2-(benzotriazol-2-yl)-4,6-ditert-butyl-phenol |
| ultraviolet absorbent uv-320 |
| 2-benzotriazole-2-yl-4,6-di-tert-butylphenol |
| uv-320 |
| FT-0608472 |
| SCHEMBL29708 |
| 2-(2'-hydroxy-3',5'-di-t-butyl phenyl)benzotriazol |
| 2-(2'-hydroxy-3',5'-di-tert.-butylphenyl)-2h-benzotriazole |
| 2-(2-hydroxy-3,5-di-tert-butylphenyl)-2h-benzotriazole |
| 2-(2'-hydroxy-3',5'-di-t-butylphenyl)benzotriazole |
| benzotriazol-2-yl-4,6-di-tert-butyl-phenol |
| 2-(2'-hydroxy-3',5'-di-tert-butylphenyl) benzotriazol |
| DTXSID4052059 |
| W-106481 |
| 2-(3,5-di-tert-butyl-2-hydroxyphenyl)-2h-benzotriazole |
| 2-(2h-benzotriazol-2-yl)-4,6-di-tert-butylphenol |
| phenol, 2-(2h-1,2,3-benzotriazol-2-yl)-4,6-bis(1,1-dimethylethyl)- |
| mfcd01075688 |
| GS-3142 |
| 2-(2h-1,2,3-benzotriazol-2-yl)-4,6-di-tert-butylphenol |
| sr-01000420895 |
| SR-01000420895-1 |
| 2-(2h-benzotriazol-2-yl)-4,6-bis(1,1-dimethylethyl)-phenol |
| Q43105370 |
| E78654 |
| kemisorb 75 |
| viosorb 582 |
| tinuvin 320 |
| eversorb 77 |
| sumisorb 320 |
| seesorb 705 |
| chisorb 320 |
| CS-W018937 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "In our previous toxicity studies using young rats, we showed that an ultraviolet absorber, 2-(2'-hydroxy-3',5'-di-tert-butylphenyl)benzotriazole (HDBB), principally affected the liver, and male rats had nearly 25 times higher susceptibility to the toxic effects than females." | ( Lack of gender-related difference in the toxicity of 2-(2'-hydroxy-3',5'-di-tert-butylphenyl)benzotriazole in preweaning rats. Ema, M; Hirata-Koizumi, M; Hirose, A; Imai, T; Kamata, E; Matsuyama, T, 2008) | 0.82 |
| "Previously, we showed that the toxic susceptibility of male rats to an ultraviolet absorber, 2-(2'-hydroxy- 3',5'-di-tert-butylphenyl)benzotriazole (HDBB), was nearly 25 times higher than that of females." | ( Gender-related difference in the toxicity of 2-(2'-hydroxy-3',5'-di-tert-butylphenyl)benzotriazole in rats: relationship to the plasma concentration, in vitro hepatic metabolism, and effects on hepatic metabolizing enzyme activity. Ema, M; Hirata-Koizumi, M; Hirose, A; Kamata, E; Kawabata, M; Matsuno, K; Matsuyama, T; Yajima, K, 2009) | 0.61 |
| " In oral repeated dose toxicity studies using 5- or 6-week-old rats, this chemical induced hepatic histopathological changes, such as hypertrophy accompanied with eosinophilic granular changes and focal necrosis of hepatocytes, and male rats showed nearly 25 times higher susceptibility to the toxic effects than females." | ( Disappearance of gender-related difference in the toxicity of benzotriazole ultraviolet absorber in juvenile rats. Ema, M; Hirata-Koizumi, M; Hirose, A; Imai, T; Kamata, E; Matsuyama, T, 2009) | 0.35 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.19) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (11.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (88.89%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||